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Abstract
Liver transplantation (LT) has become standard management of pediatric liver diseases
that lead to acute liver failure or can progress to end-stage liver disease (ESLD). Indications
for LT in pediatric patients can be classified into cholestatic disorders, metabolic liver
diseases causing liver cirrhosis, metabolic liver diseases without liver cirrhosis, acute liver
failure, acute and chronic hepatitis, and liver tumors. The most common indication of
PLT is biliary atresia. Generally, the patient is a child with biliary atresia with several prior
surgical  procedures,  extremely malnourished,  with  stigmata  of  fat-soluble  vitamin
deficiency, bleeding diathesis, uncontrolled portal hypertension and massive ascites.
Before the technique of liver splitting, pediatric patients were dependent on donors with
similar age or size. Partial liver grafts can be obtained either by splitting a cadaveric donor
organ or by living-donor liver donation. Living donor liver recipients have a shorter
waiting time. The majority of centers employ a regime of' triple therapy with predniso‐
lone, mycophenolate and tacrolimus. LT in the pediatric setting is technically challeng‐
ing due to the reduced size of the vasculature and biliary tree. Strategies for identification
and mitigation of risk factors, prevention of technical complications, and protocols for
early detection of vascular complications may reduce mortality, morbidity.
Keywords: organ transplant, liver transplant, pediatric liver disease
1. Introduction
The first successful transplant was performed by Starzl in 1967, on a 1-year-old child with
hepatoma [13–15]. The patient survived for over 12 months dying from recurrence of the liver
tumor. Throughout the next 15 years, liver transplants (LTs) were performed rarely in a very
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few centers, with survival rates of only 20‒30%. However, the quality of life in pediatric liver
transplant (PLT) patients was so good as to support these forerunners to persevere in their efforts
and to continue to refine and improve techniques and postoperative care [5].
By March 1980, the liver trials with cyclosporine began in Denver. Twelve patients entered the
study between March and September 1980; 11 patients lived for 1 year or longer [2,16]. In 1983,
a National Consensus Conference on Liver Transplantation was held in the United States,
which became a landmark in the liver transplantation history. This event concluded that liver
transplant had advanced from an experimental stage to that of a procedure with a widespread
application for patients dying of liver failure. The number of transplants performed both in
the United States and elsewhere has grown since then. The number of liver transplant (LT)
continues to grow to date as an increasing number of indications for liver replacement are
identified [5].
Liver transplantation is the treatment of choice for pediatric liver diseases causing acute liver
failure or progressing to end-stage liver disease (ESLD). These include congenital hepatitis,
hepatocellular carcinoma, biliary atresia, Wilson’s disease (WD), progressive familial intrahe‐
patic cholestasis, and other metabolic syndromes involving injury to the liver [17]. Pediatric
acute liver failure (PALF) is a complex, rapidly progressive clinical syndrome that is the final
common pathway for many disparate conditions, some known and others yet to be identified.
PALF accounts for 10‒15% of pediatric liver transplants performed in the United States
annually [18–20].
The foremost factor limiting expansion of orthotopic liver transplant (OLT) is donor availa‐
bility. In small children, scarcity of size-appropriate grafts imposes a significant barrier to PLT.
At present, waiting list mortality rate for children less than 6 years of age is four times greater
than for children of ages 11–17 years [21]. Living-donor liver transplantation (LDLT) has been
developed to address the disparity between the number candidates for transplant and the
reduced number of available organs for LT [22].
2. Indications
Various diseases that are indications for LT in pediatric patients can be classified into choles‐
tatic disorders, metabolic liver diseases causing liver cirrhosis, metabolic liver diseases without
liver cirrhosis, acute liver failure, acute and chronic hepatitis, and liver tumors. The most
common indication of PLT is biliary atresia, approximately 40% of the pediatric candidates [1].
The indications are listed in Table 1.
2.1. Biliary atresia
Biliary atresia (BA) is a disease of unknown etiology in which there is obstruction or destruction
of the biliary tree [6]. It occurs in approximately 1 of every 15,000 live births [24]. Early
diagnosis and palliative surgery—Kasai portoenterostomy are the corner stone for the
treatment of BA. In this procedure, the biliary tree is excised to expose biliary channels, and a
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Roux-n-Y loop is fashioned for drainage. The procedure is only successful if there is restoration
of biliary flow under 6 month of age and is conditional to the age when the operation is
performed, the skill of the surgeon, and the degree of fibrosis at operation [25]. BA is the main
indication for PLT worldwide and accounts for 76% transplants in children younger than 2
years; 80% of children who have a successful operation do not require transplantation before
adolescence [6,23,25].
Chronic liver failure Acute liver failure
Neonatal liver disease
Biliary atresia
Idiopathic neonatal hepatitis
Fulminant hepatitis
Autoimmune hepatitis
Halothane exposure
Acetaminophen poisoning
Viral hepatitis
Cholestatic liver disease
Alagille’s syndrome
Familial intrahepatic cholestasis (FIC)
Nonsyndromic biliary hypoplasia
Metabolic liver disease
Fatty acid oxidation defects
Neonatal hemochromatosis
Tyrosinemia type I
Wilson’s disease
Inherited metabolic liver disease
Alfa1 antitrypsin deficiency
Cystic fibrosis
Glycogen storage disease type IV
Tyrosinemia type I
Wilson’s disease
Chronic hepatitis
Autoimmune
Idiopathic
Postviral (hepatitis B, C, other)
Inborn errors of metabolism
Crigler-Najjar type I
Familial hypercholesterolemia
Primary oxalosis
Organic acidemia
Urea cycle defects
Other
Cryptogenic cirrhosis
Fibropolycystic liver disease ± Caroli syndrome
Liver tumors
Benign tumors
Unresectable malignant tumors
Table 1. Indications for LT in pediatric patients [23].
In several cases, the child needs LT in the first year of life due to the aggressive evolution of
the disease leads to cirrhosis accompanied with severe malnutrition. Consequently, technical
difficulties related to the limited dimensions of the anatomic structures are faced [26]. Hypo‐
plasia, with or without portal vein thrombosis are relatively frequent in the course of BA. These
features are related to a higher incidence of portal vein complications [27]. Previous portoen‐
terostomy procedures cause intra-abdominal adhesions increasing the morbidity due to
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intraoperative bleeding and eventual bowel perforation. Previous reports have indicated that
BA patients display lower survivals than children undergoing LT for other hepatic diseases
[26,28,29].
Infants with suspected BA should be evaluated as rapidly as possible because the success of
the surgical intervention (hepatoportoenterostomy, the Kasai procedure) diminishes progres‐
sively with older age at surgery [30]. The evaluation process involves a series of serologic,
laboratory, urine, and imaging tests. The order of diagnostic tests is prioritized based on testing
for treatable diseases first, such as biliary obstruction, infections, and some metabolic diseases.
Evaluation of biliary anatomy begins with an ultrasound. The main utility of the ultrasound
is to exclude other anatomic causes of cholestasis (i.e., choledochal cyst). In infants with BA,
the gallbladder is usually either absent or irregular in shape. When a detailed ultrasonographic
protocol is used, additional features can be identified to support the diagnosis of biliary atresia,
including abnormal gallbladder size and shape, the “triangular cord” sign, gallbladder
contractility, and absence of the common bile duct [31–34]. The triangular cord sign is a
triangular echogenic density seen just above the porta hepatis on US scan. Its presence is highly
suggestive of biliary atresia [35]. Patency of the extrahepatic biliary tree can be further assessed
by hepatobiliary scintigraphy.
The liver biopsy is important for mainly two reasons: to identify histologic changes consistent
with obstruction that warrant surgical exploration and to differentiate BA from other causes
of intrahepatic cholestasis, which would not need surgical exploration. Biopsy findings that
indicate another etiology include bile duct paucity (Alagille syndrome), periodic acid-Schiff
(PAS) positive diastase resistant granules (consistent with alpha-one antitrypsin deficiency),
or giant cell hepatitis without proliferation of ducts. Characteristic histologic features of BA
include expanded portal tracts with bile duct proliferation, portal tract edema, fibrosis and
inflammation, and canalicular and bile duct bile plugs. The earliest histological changes
associated with BA may be relatively nonspecific, and biopsies done too early may result in a
false negative [36].
Histologic findings alone cannot help to distinguish BA from other causes of obstruction, such
as choledochal cyst or external compression. Therefore, any evidence of obstruction mandates
imaging exploration and a definitive cholangiogram. The intraoperative cholangiogram is the
gold standard in the diagnosis of BA. It is essential that patency be investigated both proximally
into the liver and distally into the bowel to determine whether BA is present. If the intraoper‐
ative cholangiogram demonstrates biliary obstruction (i.e., if the contrast does not fill the
biliary tree or reach the intestine), the surgeon should perform a hepatoportoenterostomy
(Kasai HPE) at that time [37].
An increase in the number of long-term survivors of biliary atresia has been observed.
Nevertheless, the disease is still one of the most challenging problems in the field of pediatric
surgery because of progressive fibrosis, portal hypertension, and liver cirrhosis [17]. Kasai
portoenterostomy (KPE) may play a role in gaining time for liver transplantation [17,38].
Shinkai et al. [39] showed improvement of post-KPE survival rate with almost 90% for 5 years
and nearly 80% for 10 years in patients who were operated on in the 1980s. Still, despite early
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success with portoenterostomy, a few long-term survivals will present manifestations of portal
hypertension, such as esophageal and/or gastric varices, and hypersplenism. Cholangitis and/
or hepatic failure caused by progressive ongoing cirrhosis may also occur in patients with long
follow-up after KPE. The main cause of comorbidity among long-term survivals of biliary
atresia is portal hypertension. Despite the improvement in the long-term survival rate after
KPE in biliary atresia, two-thirds of patients who survived over 10 years suffer from various
complications including portal hypertension, cholangitis, intrahepatic cyst, and intestinal
obstruction in spite of successful KPE. Approximately one-third of these patients will not
present any problem. Meticulous follow-up is required since some manifestations of on-going
liver cirrhosis will present and therefore planning for liver transplantation is necessary [40].
2.2. Inherited metabolic liver disease
2.2.1. Acute liver failure in inherited metabolic liver disease patients
Metabolic diseases account for at least 10% of acute liver failure cases in North America and
Europe [19,41]. While some conditions, such as mitochondrial disease, may present at any age,
many metabolic conditions presenting as liver failure segregate within age groups. Metabolic
conditions affecting infants in the first few months of life include galactosemia, tyrosinemia,
Niemann-Pick type C, mitochondrial hepatopathies, and urea cycle defects [42]. In older
infants and young children up to 5 years of age presenting with acute liver failure, metabolic
diseases are sometimes identified [18], such as mitochondrial hepatopathies, hereditary
fructose intolerance (HFI), argininosuccinate synthetase deficiency (citrullinemia type 1), and
ornithine transcarbamylase deficiency. In older children and adolescents, Wilson’s disease and
mitochondrial disease (fatty acid oxidation defects) may cause acute liver failure [43].
2.2.2. Alpha 1 antitrypsin deficiency
Alpha 1 antitrypsin (AAT) deficiency is the most common form of inherited metabolic liver
disease in childhood in Europe. Although 50‒70% of children develop persistent liver disease
progressing to cirrhosis, only 20‒30% require transplantation in childhood or adolescence
[44,45].
The presentation of alpha 1 antitrypsin deficiency can include neonatal cholestasis. The
frequency of AAT deficiency in infants with neonatal cholestasis ranges from 1 to 10% in
different series [46,47]. AAT is an antiprotease and the natural inhibitor of the serine proteases
released by activated neutrophils [48]. The “deficiency” state is actually an accumulation of
abnormal protein within the endoplasmic reticulum resulting in liver injury in a subset of
patients by unclear mechanism [49].
2.2.3. Alagille’s syndrome
This autosomal dominant condition has an incidence of 1 case per 100,000 live births. It is a
multisystem disorder with cardiac, facial, renal, ocular, and skeletal abnormalities. The
condition is caused by mutations in the Jagged 1 gene (JAG1), which encodes a ligand of Notch
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1 [50]. The main clinical issues are cholestasis, malnutrition, and cardiac or renal disease [6].
Cholestatic liver disease is of variable severity and may stabilize by school age. It is managed
conservatively, with treatment for pruritus and malabsorption as needed. Portoenterostomy
(Kasai procedure) is not beneficial and is not recommended [51]. End-stage liver disease
develops in approximately 20% of affected children and is amenable to liver transplantation
[43,52].
2.2.4. Tyrosinemia type I
Tyrosinemia type I, also known as Hepatorenal tyrosinemia [43], is an autosomal recessive
disorder caused by a defect of fumaryl acetoacetase (FAA). There is a lifetime risk of developing
hepatocellular carcinoma (HCC) [53]. Clinical features are heterogeneous, even within the
same family. Young infants present with cholestasis and coagulopathy, which is often
disproportionate to the apparent degree of liver disease. Older infants and children may
present with chronic liver disease, with or without cholestasis, and painful crises, mimicking
porphyria [44]. Management is with a phenylalanine and tyrosine-restricted diet and nitisone,
which prevents the formation of toxic metabolites and allows normal growth and development
[55]. The long-term outcome has significantly improved with nitisone therapy and transplan‐
tation is now only indicated in those adolescents who do not respond to nitisone, or develop
HCC [6,54]. Affected individuals have increased urinary excretion of succinylacetone and
markedly elevated blood tyrosine concentration [44].
2.2.5. Cystic fibrosis
Cystic fibrosis (CF) occurs in 1 in every 3000 live births worldwide [55].
The gene defect is an abnormality in the cystic fibrosis transmembrane conductance regulator
(CFTR) located on chromosome 7q31. It is a multiorgan disease mainly affecting the lungs and
pancreas [6]. The cystic fibrosis transmembrane conductance regulator is located on the apical
surface of the biliary epithelium, explaining some of the biliary tract disease seen in patients
with cystic fibrosis [56]. Neonatal cholestasis is an uncommon presentation of cystic fibrosis,
occurring in fewer than 5% of patients with CF. In affected infants, jaundice and hepatomegaly
slowly resolve. Infants with CF are more likely to present with meconium ileus or steatorrhea
with failure to thrive [43]. Cystic fibrosis-associated liver disease (CFLD) occurs in 27‒35% of
patients and usually presents before the age of 18 years [60]. Cirrhosis and portal hypertension
occurs in 5‒10% of patients during the first decade of life and present with complications in
adolescence or early adult life [57]. The indications for LT include malnutrition unresponsive
to nutritional support, intractable portal hypertension, and hepatic dysfunction. It is essential
that transplantation be carried out before pulmonary disease becomes irreversible [58].
2.2.6. Wilson’s disease
Wilson’s disease is the most common metabolic condition associated with PALF in children
over 5 years of age [18]. It is an autosomal recessive disorder with an incidence of 1 case per
30,000 live births. The defective gene is on chromosome 13 and encodes a copper transporting
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P-type adenosinetriphosphatase (ATPase) (ATP7B) [59]. Clinical features in adolescence
include hepatic dysfunction (40%) fulminant hepatitis, chronic hepatitis or cirrhosis, and
psychiatric symptoms (35%). Neurologic symptoms may be nonspecific, but deteriorating
school performance, abnormal behavior, lack of coordination, and dysarthria are common.
Renal tubular abnormalities, renal calculi, and hemolytic anemia are associated features
[60,61].
The presence of a Coombs-negative hemolytic anemia, marked hyperbilirubinemia, low serum
ceruloplasmin, and a normal or subnormal low serum alkaline phosphatase should prompt
consideration of WD, but confirming the diagnosis remains a challenge [62]. LT is indicated
for those with advanced liver disease (Wilson’s score > 6), fulminant liver failure, or progres‐
sive hepatic disease despite therapy [60,61].
2.2.7. Other inborn errors of metabolism
LT is indicated for those metabolic disorders secondary to hepatic enzyme deficiencies that
lead to severe extrahepatic disease such as kernicterus in Crigler-Najjar type I and systemic
oxalosis in primary oxaluria. Selection and timing of transplantation depends on the quality
of life on medical management and the mortality and morbidity of the primary disease
compared with the risks of transplantation [23]. Crigler-Najjar type I is an autosomal recessive
condition caused by a deficiency of bilirubin uridine diphosphate glucuronosyltransferase
(UDPGT) [63]. Most children require transplantation in early childhood, but those with milder
forms may manage with phototherapy into adolescence. Primary hyperoxaluria is a defect of
glyoxylate metabolism characterized by the overproduction of oxalate, which is deposited as
calcium oxalate in various organs including the kidney [64]. Ideally, liver replacement should
be prior to the development of irreversible renal failure. If this is not possible, liver and kidney
replacement may be required simultaneously [65]. Children with milder phenotypes will not
require intervention until adolescence [6].
2.3. Liver tumors
2.3.1. Hepatoblastoma
The most common primary liver tumor in children is hepatoblastoma (HB), accounting for
two-thirds of all malignant liver neoplasms in the pediatric population [66]. Neoadjuvant
chemotherapy and surgical resection followed by adjuvant chemotherapy is the treatment of
choice for patients with HB. When HB shows to be unresectable or unresponsive to chemo‐
therapy, combination of chemotherapy and liver transplantation is an attractive alternative
[67]. The United States Surveillance, Epidemiology, and End Results (SEER) from 2002 to 2008
showed an incidence in HB of 10.5 cases/million in children under 1 year of age and 5.2 cases/
million in children 1‒4 years of age [68]. Histologically, HB cells resemble embryonic liver cells
and the incidence is highest at birth suggesting that the process is initiated during gestation
[69].
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Liver transplantation has resulted in long-term disease-free survival in up to 80% of children
with large solitary, and especially multifocal, hepatoblastomas invading all four sectors of the
liver [70]. While “extreme” resection of tumors without liver transplant will avoid the need
for long-term immunosuppressive therapy, hazardous attempts at partial hepatectomy in
children with major venous involvement or with extensive multifocal tumors should be
discouraged [71–75]. Only in centers that have a facility for liver transplant extensive hepatic
surgery in children should be carried out. In these centers, surgical expertise, as well as
willingness to embark on more radical surgery with a transplant “safety net” is likely to be
greater [75]. In a review of the United Network for Organ Sharing database in the United States
concerning liver transplantation in 135 children transplanted for unresectable or recurrent HB
(1987–2004), the 1-, 5-, and 10-year survival was 79, 69, and 66%, respectively [76]. The latest
European Liver Transplant Registry (ELTR) report, including 129 patients transplanted for
HB, has shown a 1- and 5-year survival of 100 and 74%, respectively [77,78].
The only absolute contraindication for liver transplantation is the persistence of viable
extrahepatic tumor deposit after chemotherapy, not amenable to surgical resection. When
macroscopic venous invasion occurs (portal vein, hepatic veins, and vena cava), liver resection
can be carried on if complete resection of the invaded venous structures is feasible. “En-bloc”
and reconstruction should be performed whenever there is evidence or suspicion of invasion
of the retrohepatic vena cava. Patients with lung metastases at presentation should not be
excluded from liver transplantation if the metastases clear completely after chemotherapy and/
or surgical resection. Liver transplant can only be performed after complete eradication of
metastatic lesions, by chemotherapy and surgical resection, of any suspicious remnant after
chemotherapy [79]. Rescue liver transplantation, after an incomplete partial hepatectomy or
when intrahepatic relapse occurs, may be a relative contraindication because of the disap‐
pointing results observed in the SIOPEL-l study and in the reported world experience [77].
2.3.2. Hepatocellular carcinoma
Unlike the adult population, the frequency of HCC in the pediatric population is low; therefore,
the experience in the application of liver transplantation in the pediatric population for HCC
is limited [80–83]. Experience with liver transplantation in children with unresectable HCC is
somewhat limited but results have significantly improved over the recent years. The Milan
criteria—no more than three tumors, each not more than 3 cm in size, or a single tumor, not
more than 5 cm in diameter, and no evidence of extrahepatic disease or vascular invasion is
commonly used to determine which patients benefit the most with LT [84]. Recently, it has
been suggested that the present cut-off for tumor size might be expanded to 6.5 cm or 7 cm, in
an otherwise normal liver [89, 90]. Data suggesting that Milan criteria can appropriately
identify children with a low-risk tumor recurrence of after transplantation is not yet available.
The Milan criteria are derivative from experience treating adult patients with cirrhosis,
whereas HCC in children usually is not associated with cirrhosis. The role of OLT in noncir‐
rhotic liver is unknown due to lack of prospective trial in children. Furthermore, there are
differences in biology of HCC in adults and in children [85]. The different molecular findings
include mutation of c-met gene in children; lower levels of glycin D1 (regulatory protein of G1
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phase cycle) expression in children; and higher incidence of loss of heterozygosity on chro‐
mosomal arm, 13q, in children [85]. In patients whose disease is confined to the liver, the use
of liver transplantation is indicated.
2.4. Acute Liver Failure
Viral hepatitis A and B are the most common causes of acute liver failure in the developing
world [86,87]. However, in the United Kingdom and United States, indeterminate hepatitis is
the most common cause and has the worst prognosis for spontaneous recovery [18]. The main
indications for LT for acute liver failure in adolescence are drug induced, infectious hepatitis,
or metabolic disease (e.g., Wilson’s disease) [18,88]. Many different drugs cause acute liver
failure, including antibiotics, antituberculosis therapy, antiepileptic therapy, and acetamino‐
phen poisoning [89]. Adolescents have a lower incidence of liver failure with acetaminophen
overdose than adults, possibly because of the effect of hepatic maturation and glutathione
production [90]. Transplantation is more likely to be required if the overdose was taken with
another drug (e.g., lysergic acid diethylamide [LSD], ecstasy) or with alcohol [91]. Persistent
coagulopathy (INR > 4), metabolic acidosis (pH < 7.3), an elevated creatinine (>300 mmol/l),
and rapid progression to hepatic coma grade III are indicatives for liver transplant. Cerebral
edema may persist despite evidence of hepatic regeneration and recovery and influence
postoperative recovery.
Once the diagnosis of liver disease is made, the most important assessment is to determine the
severity of the liver disease and its projected outcome. Patients with evidence of end-stage
liver disease, including variceal hemorrhage, intractable ascites, hepatorenal syndrome,
recurrent infection, and portosystemic encephalopathy, are candidates for immediate listing
for transplantation. Selected patients with well-compensated Child’s A cirrhosis and isolated
variceal bleeding benefit from surgical portosystemic shunting. The success of transplantation
in patients with sequel of end-stage liver disease has also heralded an increasing willingness
to apply transplantation in patients with life-disabling complications of liver disease conse‐
quent to severe metabolic consequences of chronic liver disease [92].
Thus, the indications for PLT are significantly different to indications in adult LT recipients.
In the past, PLT was only performed in curative intent. Nowadays, if life expectancy and/or
quality of life can be significantly improved, PLT is also performed. Children diagnosed with
metabolic liver diseases not resulting in liver cirrhosis, the indication for LT has to be cautiously
evaluated. LT should be performed when the disease can either be cured or if extrahepatic
manifestations can be significantly improved [1].
3. Contraindications for transplantation
The few contraindications include severe systemic sepsis—particularly fungal sepsis, at the
time of operation; malignant hepatic tumors with extrahepatic spread; severe extrahepatic
Pediatric Liver Transplantation
http://dx.doi.org/10.5772/63477
181
disease that is not reversible following LT (e.g., severe cardiopulmonary disease for which
corrective surgery is not possible), or severe structural brain damage [23].
4. Preoperative management
When transplantation was still perceived as experimental, potential candidates were referred
to very late in their course of end-stage liver disease. Generally, the patient was a child with
biliary atresia with several prior surgical procedures, who was extremely malnourished, with
stigmata of fat-soluble vitamin deficiency, bleeding diathesis, uncontrolled portal hyperten‐
sion, and massive ascites. One could not imagine a poorer candidate for major surgery.
Unfortunately, this is still reality in many centers [2].
Correct preparation before transplantation requires a multidisciplinary approach. The use of
new milk formulas specially developed for cholestatic children, parenteral nutrition, may be
necessary to correct the nutrition deficit [93]. Gastrointestinal bleeding from esophageal
varices should be prevented with sclerotherapy [93], variceal banding [94], and transjugular
intrahepatic portosystemic shunt in older children [95]. The remarkable enhancement in the
outcomes of liver transplantation, including children, has encouraged an earlier referral,
allowing a more elective approach toward liver transplantation [2].
Immunizations should be administered to solid organ transplant candidates as early as
possible in the transplant evaluation in order to optimize immune responses and provide
immunity to pathogens against which there is only a live vaccine (measles, mumps, rubella,
varicella, and zoster). Standard age-appropriate vaccines, as well as vaccines indicated for
immunocompromised hosts (e.g., pneumococcal vaccines in adults), should be administered
2‒6 months following transplantation, once maintenance immunosuppression levels have
been attained. Inactivated vaccines are generally considered to be safe following solid organ
transplantation [96].
Live vaccines (measles, mumps, rubella, varicella, zoster, and intranasal influenza vaccine) are
not recommended in the majority of solid organ transplant recipients. An exception is varicella-
nonimmune pediatric renal or liver transplant recipients who are receiving minimal or no
immunosuppression and who have had no recent allograft rejection; such individuals may
receive the varicella vaccine [96].
The measles, mumps, and rubella vaccine is considered safe in household contacts of solid
organ transplant recipients. We suggest administering the varicella vaccine to nonimmune
household contacts. The zoster vaccine should be administered to household contacts when
indicated. Vaccinees who develop a rash should avoid contact with transplant recipients for
the duration of the rash [1].
In biliary atresia patients, which is the most frequent indication, a sequential strategy with a
single attempt at surgical correction, Roux-en-Y portoenterostomy as described by Kasai [97],
followed by liver transplantation, when it fails, is consensus by pediatric surgeons [104]. At
present, most infants who do not achieve remission following portoenterostomy are referred
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to and transplanted under the age of 1 year. Malatack et al. [98] proposed a score to choose the
timing of transplantation for children with chronic liver failure. Though such a score can be
beneficial, it is suggested that liver transplantation should be performed as soon as an
appropriate donor is found, even for children in stable condition, at least when the indication
is straightforward at any age of the child.
Due to better understanding of the pathophysiology and/or increased of clinical experience,
many contraindications accepted in the past are not presently valid. An example is hepato‐
pulmonary syndrome, which can associate with any type of chronic liver disease. Room air
PaO2 level lower than 60 mmHg has been described to be associated with prohibitive mortality
after liver transplant [99]. Differently, regardless of the severity of the syndrome, others have
shown complete reversion of hepatopulmonary syndrome after LT [107].
4.1. Psychological preparation
A skilled multidisciplinary team, including a psychologist, is essential for counseling and
preparation of the patient and his/hers family. Young people need to be involved in the
decision making wherever possible, and previous experience of illness, knowledge about their
condition and treatment, previous/current adherence to prescribed medical regimens, and self-
management behaviors need to be explored. Parents and appropriate relatives must be fully
informed of the necessity for LT in their child and of the risks, complications, and the long-
term implications of the operation. Particularly, careful counseling is necessary for parents and
children being considered for transplantation because of extrahepatic disease due to an inborn
error of metabolism. As these young people are not dying from liver disease, they may find it
difficult to accept the risks and complications and the necessity for compliance with long-term
immunosuppression [6].
4.2. Psychosocial evaluation of live organ donors
Adequate psychosocial evaluation includes assessment of the motivation for donating,
decision making and informed consent process, donor-recipient relationship, adequacy of both
financial and social support, behavioral and psychological health, and substance use history.
A complete assessment of a potential living donor should also address obstacles such as
impression management and explicit deception. It should also include ethical aspects, such as
the right to donate, donor autonomy, freedom from coercion, and “reasonable” risks to donors.
The Transplantation Society Ethics Committee emphasizes that is essential when considering
living organ donation, that the well-being of donors, including survival, quality of life, and
psychological and social well-being, outweighs the risks to the donor-recipient pair, which
include death and medical, psychological, and social morbidities [100]. Like to the psychosocial
evaluation of the recipient, the attention should be on the interaction of risk versus protective
factors for each donor [109]. Although recent research identifies the needs for standard criteria
[101], live organ donor evaluations should be viewed within both individual and contextual
frameworks [22].
Pediatric Liver Transplantation
http://dx.doi.org/10.5772/63477
183
5. Surgical techniques
Liver transplantation has gained from the knowledge of anesthesiologists handling babies
with serious conditions. The pediatric anesthesiologist is an essential member of the team. As
in any long operation, exact correction of blood loss, continual monitoring of electrolytes and
blood gases, correct identification and treatment of bleeding diathesis, and maintenance of
body temperature and diuresis are fundamental. Alongside a correct comprehension of all the
surgical techniques, good tactics and technical expertise, proper attention by the surgeon to
hemostasis is essential. Although limitation of graft ischemia time is important, the patient
will be better off at the end of surgery if the operative field is dry and the small bowel has been
preserved from damage during the tedious dissection of tight adhesions, rather than been
rushed through surgery by a hurried surgeon [2].
Figure 1. Examples of surgical techniques for orthotopic liver transplantation.
Prior the development of the technique of liver splitting, PLT was dependent on donors with
similar age or size. In the early 1980s, Christoph Broelsch and Henri Bismuth were the first
applying the technique of reduced-size LT in children [102,103]. Rudolf Pichlmayr performed
the first split LT offering one cadaveric liver to two recipients in 1988 [104]. However, pediatric
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deceased donors as well as organs suitable for split LT remain rare. The numbers of PLTs
performed significantly exceed the number of available pediatric organ donors [1,105].
LT in children is comparable to adult LT (piggy back or conventional technique) when full size
grafts are transplanted. Partial liver grafts can be obtained either by splitting a cadaveric donor
organ or by living-donor liver donation. When liver-splitting technique is used, the anatomical
determination of the eight liver segments first described by Couinaud [106,107] in 1957 is
essential. Figure 1 depicts the surgical options for OLT.
The splitting procedure can be performed as anatomical splitting, dividing the liver at Cantlie’s
line, and splitting along the falciform ligament [117]. When the left lateral segment divided,
the technique is much easier to perform than the true right/left lobe split procedure. Addi‐
tionally, the left lateral segment is preferentially used in PLT. It is the smallest part of the liver
when compared to the extended right, the anatomical left, or the right liver lobe.
In small infants, even the left lateral segment of the liver often is too large and techniques to
cut down left lateral lobes may be used to prevent graft-size mismatching and the so-called
“large-for-size” syndrome [108]. Not rarely, primary closure of the abdominal wall after PLT
is not feasible and should not be enforced in order to avoid increase in intra-abdominal
pressure. Excessive increase in intra-abdominal pressure may compromise graft perfusion. In
such occasions, abdominal wall closure is performed in stages during the first week post-
transplant or accomplished by using mesh grafts. This allows for a continuous recovery of the
graft from reperfusion injury and edema [109].
5.1. Auxiliary transplantation
Auxiliary partial orthotopic LT (APOLT) is an alternative technique for LT in patients with
acute liver failure or in children with metabolic liver diseases without primary hepatocellular
dysfunction or cirrhosis. In this technique, a partial graft is implanted without entirely
removing the native liver. Gubernatis et al. reported the first successful case in a patient with
acute liver failure. After her recovery, the native liver has regenerated and immunosuppressive
treatment could be withdrawn [110,111].
In patients with metabolic diseases, APOLT may provide sufficient liver mass to correct the
hepatic metabolic function. If the graft fails, the patient’s native liver is still present to secure
general liver function [112]. When APOLT is performed in acute fulminant liver failure, the
immunosuppressive therapy can be stopped if the native liver recuperates, resulting in an
atrophy of the transplanted liver [113].
5.2. Living-donor liver donation
After successful implementation of split-liver LT in PLT, this technique leads to the first living-
donor liver transplant (LDLT). In 1989, the first series of LDLT in pediatric recipients was
performed in Chicago [114], after the pioneer work of Raia et al. [115] in Brazil. As of today,
LDLT is an established procedure and the main form of LT due to scarcity of deceased donor
organs in most East-Asian countries [116]. In western countries and especially in the UNOS
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area, use of living-donor organs for LT is less frequent and within UNOS constantly <5% of
LT over the last years [117]. Within the European Transplant Network, rates of LDLT in PLT
are steadily increasing.
Retrospective analyses have shown favorable or equal results as compared to PLT after
deceased donor liver transplant (DDLT) [118–126]. When performing LDLT the scenery
include an optimal healthy donor, minimal ischemic time, elective surgery, and timing of
transplantation according to the recipients’ need. This is particularly pertinent for pediatric
patients. During a waiting time for PLT, the underlying disease can complicate and psycho‐
social long-term morbidity may develop pediatric patient. It has been shown that long-term
outcome after PLT significantly correlates with the severity of morbidity at PLT. In a early
publication, significant independent predictors of survival after OLT in children with end-
stage liver disease were bilirubin (p=0.0024), lower weight (p=0.034), and albumin (p=0.039).
Post-transplantation survival rates was statistically significant difference at 1 year (57% vs.
90.5%) and 4 years (49% vs. 90.5%) after OLT(p=0.0001), when one or more of these risk factors
- bilirubin >340 μmol/L, lower weight <−2.2 and albumin < 33 g/L, were presente [127]. LDLT
offers the possibility and advantage of optimal timing of the transplant procedure before
severe morbidity develops.
Living-donor livers recipients have a shorter waiting time when compared to recipients of
organs from deceased donors. This reflects in a reduction of waiting list mortality. Neverthe‐
less, live donors are not deprived of risk. Also to considerer is the fact that LDLT is surgically
more challenging than whole organ transplantation. Donor major complications, exceeding
Clavien’s classification grade II, were described in up to 44% after right-lobe LDLT with a
mortality risk up to 0.8% [128–130]. Donors of right liver lobe experience operating procedures
with longer duration, have significant longer hospital stay and require more blood transfusions
[131,132]. For PLT, in most cases, the left lateral segment donation is sufficient. The complica‐
tion rates after full left lobe or left lateral lobectomy are significantly lower than right lobe
donation [133–135]. In order to decrease morbidity and mortality after liver donation, a
thorough evaluation of the potential donor is essential to detect and exclude potential
increased medical risk factors for the otherwise healthy donor.
5.3. Living related donor liver transplantation in children
5.3.1. Surgical technique
The donor procedure is performed first, except when recipient’s diagnosis is malignant liver
tumor. The recipient surgery usually starts immediately after the quality of the graft is assured
to minimize the cold ischemia time. Left lateral hepatectomy is performed without clamping
of the portal triad. The vessels were divided after completion of the parenchymal transection.
The whole hilum is dissected and the left hepatic artery is identified. Subsequently, dissection
is confined to the left branch of the portal vein and to the left hepatic artery. Minimal dissection
was performed around the left hepatic duct to avoid damaging its blood supply. At bench
surgery, the graft is perfused with preservation solution.
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The liver implantation technique consists of the anastomosis of the left hepatic vein to the
native inferior vena cava. This anastomosis can be performed by direct suturing of the donor
hepatic veins to the recipient hepatic veins; by a triangular anastomosis after creating a wide
triangular orifice in the recipient inferior vena cava at the confluence of all of the hepatic veins;
or a wide longitudinal anastomosis in the anterior wall of the inferior vena cava. Subsequently,
the portal vein is anastomosed to the trunk of the recipient’s portal vein in an end-to-end
technique [136].
The liver graft is reperfused after conclusion of the portal vein anastomosis. For the recon‐
struction of the artery, microsurgical techniques are necessary. The graft hepatic artery is
anastomosed to one of the stumps of the main branches or to the trunk of the proper hepatic
artery of the recipient in end-to-end fashion using 9-0 or 10-0 prolene sutures. The arterial
anastomosis should be performed using microsurgery techniques under surgical microscope
(magnification, 8×) or surgical loupes (magnification, 6×), depending on the size of the arteries.
Biliary reconstruction is achieved by a Roux-en-Y hepaticojejunostomy. Occasionally, an end-
to-end duct anastomosis can be performed [136].
6. Post-transplant care
Immediately after the transplant, the patient is usually ventilated in intensive care for 24-48 h.
Graft function is assessed with coagulation studies, blood sugar and acid-base balance, and
liver function tests. Initially in the post-operative period, high transaminase levels are usually
observed that progressively fall during the first few postoperative days. A rapid reduction of
jaundice is an indication of a well-functioning graft.
When abnormal liver function tests are detected, a specific protocol of investigations to
determine the cause is necessary. In patients with a t-tube, a cholangiogram will demonstrate
patency of the biliary tree. In patients without a t-tube, an ultrasound of the liver can exclude
biliary obstruction and demonstrate patency of the portal vein and hepatic artery. In the
suspicion of a thrombotic event, angiography should be performed to confirm it. The gold
standard for diagnosing a rejection episode is needle biopsy. Liver biopsy should be carried
out subsequently. Other diagnoses such as preservation injury or viral hepatitis in the graft
can also be diagnosed. For confirmation of viral infections, specific antibody tests usually are
necessary [5].
7. Immunossupression
As in adult LT, the introduction of calcineurin inhibitors (CNI) in the early 1980s gave way to
long-term survival also for pediatric transplant recipients and until today remains the
backbone of immunosuppression practices [1,3,137]. The most popular immunosuppression
drugs combination comprises low doses of prednisolone, mycophenolate, and tacrolimus.
Despite the high effectiveness of these medications in controling the imune response, rejection
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is a reality in the majority of liver transplant recipients which can be controlled with the
intensification of the steroid dose. Higher doses of immunosuppression are usually associated
with a lower incidence of rejection. On the other hand, at the same time, a higher infection rate
with considerable morbidity and even morality appears. Moreover, each of the agents has
specific toxic effects [5]. Observations made by several groups indicate that after liver trans‐
plantation in children require more immunosuppression than adults, with a higher incidence
of steroid sensitive and steroid-resistant acute rejection episodes [137].
The period of highest risk for immunologic reactions between graft and host usually is in the
early post-transplant phase. Consequently, higher dose of immunosuppression is required
during this period. Most protocols include induction therapy, usually interleukin-2 receptor
antibodies especially in the pediatric transplant population (Basiliximab® and Daclizumab®),
in association with corticosteroids and calcineurin inhibitors (cyclosporine A and tacrolimus)
as maintenance therapy [138–143]. In the pediatric transplantation community, the use of other
mono- or polyclonal antibodies—monoclonal anti-CD3 antibody preparations (OKT3) and
rabbit or equine antithymocyte globulin, for induction therapy has not been adopted. These
potent agents can cause undesired short—and uncertain long-term effects on the developing
organism and immune system [144]. Several reports showed that the lower doses of immu‐
nosuppression can be used based on the individual needs, particularly in pediatric cases which
can, in long-term, improve the quality of life of these patients minimizing undesired side effects
[145–148].
Common side effects of immunosuppressants include diabetes, deficiency of growth, hyper‐
tension, nephrotoxicity, hyperlipidemia, neurologic alterations, hypertrichosis, and bone
marrow suppression. Ideal levels of immunosuppression are hard to obtain due to great
differences between individuals as well as within the same individual over time. Multiple
combination protocols, such as mycophenolate-mofetil and mammalian target of rapamycin
inhibitors (sirolimus and everolimus), with and without CNIs have been introduced for
maintenance therapy also in pediatric solid organ transplant based on increasing data to safety
aspects in the use of different immunosuppressant drugs in the adult population [149–156].
It is well established that long-term immunosuppression increases the risk of infectious and
malignant complications. Other side effects, such as nephrotoxicity, disturbances of the lipid
profile, arterial hypertension, and cardiovascular disease, are also of concern. These side effects
can jeopardize both quality of life and life expectancy. Especially in pediatric liver recipients
whose survival can be expected to be more than a few decades; consequently prevention of
these side effects is a major objective. The reduction of the global immunosuppression in the
first months after the procedure, concerning the total amount of steroids and the target blood
levels of calcineurin inhibitors, is the main goal. The use of tacrolimus has allowed complete
withdrawal of steroids within the first posttransplant year in most patients, which has been
proved to be beneficial. New protocols, specifically designed for children to test new immu‐
nosuppressive compounds as well as tolerance inducing strategies, have been more easily
introduced [2].
Although immunosuppression drugs is still recommended after liver transplantation, several
studies have shown that particularly patients who are transplanted in the early years or receive
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a parental living liver donation could develop an evident degree of immune tolerance
concerning the graft. Single center experiences demonstrate that patients who were withdrawn
from immunosuppression because of medical reasons (such as renal insufficiency) or due to
noncompliance suggest that around 20% of liver transplant patients develop operationally
tolerance regarding the graft [157–162]. Another more aggressive approach to induce immune
tolerance in solid organ transplantation is to combine solid organ transplantation with
hematopoietic stem cell transplantation from the same donor [1,163–165].
Complete freedom from immunosuppression or significant withdrawal of immunosuppres‐
sion is possible in long-surviving recipients of liver allografts [159,166,167]. The drug weaning
protocol established for pediatric liver transplant patients at the University of Pittsburgh
includes long-term survivors who are medically compliant and have normal liver function
without recent acute rejection episodes within the past 2 years. Drug withdrawal was begun
at a mean time of 6 years after liver transplantation. The baseline immunosuppressant of
tacrolimus or cyclosporine was weaned at 2-month to 3-month intervals as long as hepatocel‐
lular enzyme tests remained stable. Liver injury tests of aspartate aminotransferase (AST),
alanine aminotransferase (ALT), gamma glutamyltransferase (GGTP), and bilirubin are
monitored weekly after changes in drug dosage. Tacrolimus or cyclosporine levels are not used
in monitoring because baseline levels in this patient population are frequently low or unde‐
tectable. Liver biopsy is done for sustained alterations in liver tests. Forty percent (17 of 43) of
the patients were off immunosuppression, with a mean time from weaning of 1.7 years. No
patient or graft loss has occurred. Rejection has occurred in 14% of patients (6 of 43), being
mild in two patients and mild to moderate in four patients, prompting switch to tacrolimus
from cyclosporine-based immunosuppression. Pediatric patients have the greatest potential
benefit from the significant dosage reductions or complete drug withdrawal that can be
potentially realized [2].
However, it is not without risk and it must be done with great care because no marker is
available to identify the patients who have developed graft acceptance operational tolerance
[168]. Three main objectives should be pursued in PLT regarding immunosuppression: (1)
reduction and individualization of immunosuppression in order to diminish long-term side
effects; (2) maintenance of long-term allograft function; and (3) monitor and induce tolerance
through the development of specific protocols, as well as identify operationally tolerant and
nontolerant patients [1].
8. Adherence
Nonadherence to the medical regimen is part of the risk-taking spectrum of behavior [77], and
approximately 33‒50% of adolescents with a chronic illness are nonadherent in some way with
their treatment protocol [169]. There is a clear association between medication nonadherence
and unfavorable transplant outcome.
Several studies investigate the role of different factors predisposing to medication nonadher‐
ence [170]. In a recent study, 75% of post-LT adolescents were nonadherent and reported
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poorer health perceptions, lower self-esteem, more limitations in social and school activities,
and poorer mental health than those who were adherent [171]. Factors such as history of
substance abuse, previous psychiatric problems, older age, female gender, and living in a one-
parent household have been associated with poorer adherence [172,173].
Nonadherence to medication is associated with increased medical complications and higher
rates of rejection and graft loss [174–176]. In addition, other aspects of nonadherence include
clinic nonattendance, missing routine blood tests, and inconsistent timing of medications. The
desire to be like their friends can result in nonadherence to different aspects of the treatment
regimen. The monitoring and management of nonadherence can be challenging, necessitating
a nonjudgmental approach, with a focus on individual adherence plans, improved education,
behavioral strategies to encourage self-management and self-motivation and a recognition of
the role of treatment burden for patients, and their families [6,177].
9. Complication
The main causes of graft loss in the first week include primary nonfunction (PNF), hepatic
artery or portal vein thrombosis, systemic sepsis, and multiorgan failure (<10%). Other
significant early complications are acute (50%) or chronic rejection (10%), biliary leaks/
strictures (5–25%), viral infections (especially cytomegalovirus (CMV) and Epstein Barr virus),
and acute kidney injury and fluid imbalance [7–12]. The most frequent complications are listed
in Table 2.
Complications after liver transplant
Hemorrhage
Primary nonfunction
Hepatic artery thrombosis
Acute rejection
Chronic rejection
Biliary leak/stenosis
Infection
 Bacterial
 Opportunistic
  Viral (e.g., CMV)
  Fungal
  Pneumocystis
Acute renal failure
Fluid imbalance
Table 2. Complications after liver transplant.
Intraoperative bleeding in PLT is commonly less of a problem than in adults, even though the
majority of the children will have had previous surgery on the liver. This can be explained by
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the fact that portal hypertension as measured by portal vein pressure is less severe in the child
than in the adult, possibly consequence of more effective collateral vessel formation [5].
Thrombosis of the hepatic artery is a major concern in PLT with rates varying from 10 to 25%.
This ischemia, when occurring in the early posttransplant period, produces either acute graft
failure or biliary tree infarction with bile leakage and intra- or extrahepatic abscess formation
[5]. Early hepatic artery thrombosis (HAT) is the most common form of vascular complication
and is the main cause of graft loss in pediatric living-related liver transplantation (LRLT) [178].
Early diagnosis and treatment can prevent biliary tract and parenchymal damage [179]. Bekker
et al reported an incidence for early HAT in pediatric LT of 8.3% compared to 2.9% in adults.
[180]. Hepatic artery stenosis and thrombosis can result in allograft ischemia, which is
associated with high mortality and morbidity rate. Arterial complications are frequently
diagnosed first by Doppler ultrasound followed by CT angiogram or angiography. Doppler
ultrasound showed a sensitivity of 100%, a specificity of 99.5%, a PPV of 95% and NPV of 100%,
and overall accuracy of 99.5% in early diagnosis of HAS [179]. According to the interval
between LT and development of thrombosis, HAT can be divided into early (within 4 weeks)
and late. Usually, early HAT may be the result of technical problems and can have dramatic
presentation [181]. Due to the fact that early HAT has a higher mortality comparing to late
HAT, intervention is required as urgent procedure [182]. Late HAT is usually due to ischemic
or immunologic injuries. Patients with late symptomatic HAT can be initially treated with
biliary stent placement and/or endovascular interventions [181].
Positive CMV antibody in donor and negative CMV recipients has been shown to be associated
with late HAT [183–186]. Some authors also suggest that perioperative hypercoagulable state
as the possible underlying cause for hepatic artery thrombosis [180–187]. Although urgent
retransplantation is considered the main therapy for early HAT, endovascular interventions,
including PTA, intra-arterial thrombolysis (IAT), and stent placement, may be alternative
treatments.
Venous complications after PLT include caval/hepatic vein and portal problems. Clinical
manifestations of portal vein stenosis (PVS) include ascites, anemia, splenomegaly, and
gastrointestinal bleeding [188–191]. Platelet counts may be below normal limit in pediatric
patients with PVS due to hypersplenism [192]. The incidence of portal vein complications is
usually higher in pediatric recipients than in adults. Smaller portal vein diameter, size disparity
between donor’s and recipient’s portal vein, and short pedicle of the donor’s portal vein are
risk factors for portal vein complications [193–196].
Clinically hepatic vein obstruction (HVO) is analogous to Budd-Chiari syndrome [197]. HVO
is a general term reflecting any obstruction of the hepatic veins caused by either compression
and twisting of the anastomosis. It can be caused by graft regeneration or by intimal hyper‐
plasia and fibrosis at the anastomotic sites [198]. Risk factors related to portal vein complica‐
tions include technical problems, young age, body weight <6 kg, the recipient’s portal vein size
<5 mm, graft rotation, previous splenectomy, simultaneous thrombectomy for pre-existing
PVT, and use of venous conduits for portal vein reconstruction [9,193,199–204]. Cold ischemia
time longer than 12 h can also be a impose risk for developing venous problems. Portal vein
stenosis is mostly associated with cryopreserved vein for portal conduits. Portal vein hypo‐
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plasia is one of the main risk factors for developing vascular complications in pediatric
recipients of LT, particularly when biliary atresia is the indication for LT [205,206]. Suzuki et
al. [207] reported a portal vein diameter of <3.5 mm to be the single most sensitive and specific
predictor of portal vein stenosis.
Endovascular interventions are less invasive treatment for post-LT vascular complications
particularly in pediatric patients. In cases of post-LT HVO, percutaneous endovascular
treatment with balloon dilation and/or stent placement can be used as a safe treatment with
high success rate. Complications, such as ascites, renal failure, lower limb edema, and
splenomegaly, can be resolved after endovascular interventions [208]. Simultaneous obstruc‐
tion of HV and IVC can also be treated with endovascular interventions. However, isolated
HV stenosis is better treated with balloon-expandable stent treatment than with balloon
dilation [209].
Although balloon dilation is an effective and relatively safe procedure for treatment of portal
vein stenosis, 28–50% of these patients may develop recurrent PVS [210–213]. Previous reports
suggest stent placement and repeated balloon dilation as solutions for this problem [212,213].
Sanada et al. [202] showed combined anticoagulant therapy using LMW heparin, warfarin,
and aspirin can significantly lower the risk of recurrent PVS [214].
9.1. Biliary complications
The presentation of biliary complications is quite variable. The diagnosis biliary leakages (BL)
usually are straightforward and presents early in the posttransplant period. Biliary stenosis
(BS) has a more indolent progression and usually is diagnosed later. BS demands a high index
of suspicion because in the initial phases the clinical picture can be confused with rejection,
infection and primary disease recurrence [215].
Early complications, occurring within 30 days of the transplant, usually are consequence of
technical problems. These include handling and harvesting of the graft, preservation injuries,
surgical technique of biliary reconstruction, or even vascular insufficiency [216]. Late compli‐
cations, occurring after 90 days posttransplant, are classified into anastomotic (AS) and
nonanastomotic strictures (NAS). NAS are associated to the use of ABO-incompatible grafts,
preservation injury, opportunistic infections, recurrent hepatitis, ductopenic rejection,
recurrent primary sclerosing cholangitis (PSC), stones or casts, posttransplant lymphoproli‐
ferative disorder or other tumors [216].
Long cold ischemia time, hepatic artery thrombosis (HAT), CMV infection, and chronic
rejection constitute risk factors for biliary anastomotic complications (leaks and strictures).
Also, tissue hypoxia at level of the anastomosis, secondary to hepatopulmonary syndrome,
can increase the frequency of biliary complications after liver transplantation [217]. Multiple
bile ducts, requiring reconstruction or more than one biliary anastomosis is an independent
risk factor for the development of biliary complications with a higher incidence of biliary
complications when compared with a single duct (21% versus 9%, respectively) [218].
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Treatment strategies are based on the type and severity of the complication and the biliary
reconstruction technique applied, duct-to-duct anastomosis or hepaticojejunostomy. Nonop‐
erative management is the first-line approach, and success can be achieved in 70‒90% of all BS
cases [219–222]. A novel magnetic compression anastomosis has been recently described.
Transmural compression with two magnets causes gradual ischemic necrosis, thus creating a
new anastomosis between the dilated duct and small intestine or bile duct. This technique has
been applied in only few cases, and further experience is necessary before it has broader
indications [215,223,224].
The majority of patients will experience at least one episode of acute rejection. However,
usually it is treated increasing the steroid. Small bile ducts destruction shown on biopsy is
typical finding of chronic rejection. This type of rejection is not reversible by increasing
immunosuppression. Repeated biopsy with histological confirmation is necessary to establish
this diagnosis. When chronic rejection occurs, the only treatment is retransplantation [5].
Immunosuppressed patients have a higher risk for infection complications. Common bacterial
infections, usually in the respiratory and biliary tracts, opportunistic infections are a potential
problem. The commonest of these are cytomegalovirus and fungal infections. Donor and
recipient CMV status matching of both graft and blood products can minimize CMV infections
[5].
When CMV-negative patient receives a CMV-positive graft, prophylactic treatment with
acyclovir has been shown to be effective in minimizing the severity of any resulting CMV
infection. Fungal infections are not rare after liver transplant, since the majority of children
with chronic liver disease are heavily colonized with candida. Limited use of broad-spectrum
antibiotics and oral antibiotic prophylaxis may reduce the incidence and severity of fungal
sepsis. Pneumocystis infection is an additional risk in these patients. Any of these infections
is associated with a high mortality. Prophylaxis with oral cotrimoxazole is nearly always
effective for these risks [5].
Another rare complication of LDLT in pediatrics is the graft rotation. Previous studies showed
that the graft rotation can lead to venous outflow obstruction and suggested stabilization of
the graft to avoid this complication [225,226]. Several surgical factors might have an important
role in preventing vascular thrombosis, especially in the transplantation of live donor or split
liver allografts. Adequate inflow in the donor vessels is also important to reduce vascular
complications. The use of interposition grafts (arteries or veins) is stimulate in the case of small-
caliber vessels or a fibrotic and small portal vein, common observed in children with biliary
atresia [224].
Oversized grafts are prone to compression after abdominal wall closure, which may compro‐
mise the flow in the afferent hepatic vessels increasing the risk for thrombosis. Delayed
abdominal wall closure is recommended in these situations, avoiding tight wound closure,
and consequently avoiding augmented intra-abdominal pressure. Administration of antipla‐
telet agents early in posttransplant, such as aspirin, has been advocated to prevent HAT [227,
228].
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10. Conclusion
In conclusion, LT in the pediatric setting is technically challenging due to the reduced size of
the vasculature and biliary tree. Discrepancies in portal vein and hepatic arterial diameter
between the donor and recipient are expected. Despite technical evolution of pediatric liver
transplantation, vascular complications are still a significant cause of allograft loss, reflecting
in increase of postoperative morbidity and mortality. Arterial complications are more com‐
mon, occur early in the postoperative period, and are associated with high rates of graft loss
and patient mortality. On the other hand, venous complications are less frequent usually
occurring in the late postoperative period with no significant effect on graft loss or mortality
rates. Important strategies for reduction of mortality, morbidity, and the need for retransplan‐
tation include detection and mitigation of risk factors, avoidance of technical complications,
and protocols for prompt detection of vascular complications.
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